http://www.esmo.org/events/vienna-2012-congress/program.html
--> The abstracts highlighted below deal with identified groups of cancer patients, namely women and adolescents, and highlight peculiarities of diagnosis, treatment and care which could offer important insight for a better prognosis for these patients.
Breast cancer and weight Abstract 248O Analysis of correlation between weight at diagnosis, weight gain after breast cancer treatment and recurrence in women with early stage breast cancer (EBC) P. Fedele, Ospedale Perrino, Oncologia Brindisi, Brindisi/ITALY
Breast cancer, early stage, Proffered Papers Moderators: P. Ellis, Dr, E. De Azambuja, Dr, I. Smith, Prof Sunday, September 30, 2012; 14:00 - 15:45 Abstract 327PD Body mass index and prognosis of women with metastatic breast cancer A. Gennari, Eo Galliera, SC Oncologia, Genoa/ITALY
Breast cancer, locally advanced and metastatic, Poster Discussion Moderators: T. Bachelot, Dr., G. Curigliano, Dr Monday, October 1, 2012; 12:45 - 13:45 Abstract 380 Impact of body mass index (bmi) on disease free survival and likelihood of pathologic complete response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy. A. Armengol-Alonso, Oncologia Medica, Hospital Clinic y Provincial de Barcelona, Barcelona/SPAIN
"Several studies have shown that obesity is an adverse prognostic factor in early breast cancer and leads to an increased risk of recurrence and breast cancer-related death. An important randomized trial (the Women's Intervention Nutrition Study) has shown that women with early breast cancer randomized to a diet designed to reduce fat intake after breast cancer surgery had a lower risk of recurrence than those on a normal diet. An important issue here, although certainly not the only one, is that post menopausal obese women may have more circulating estrogen since a lot of this is produced in fatty tissue. The aromatase inhibitors, now widely used in the treatment of early breast cancer work by suppressing estrogen, and there is some evidence that they may not be so effective in suppressing estrogen synthesis in obese women. An important new study at ESMO 2012 has produced further evidence that women who gain weight after surgical treatment for early breast cancer have a higher risk of recurrence than those that do not. It looks therefore that avoidance of weight gain may be a very important tool in the fight against breast cancer recurrence, in addition to specialized drug treatment."
Ian Smith, UK, Chair, ESMO 2012 Early Breast Cancer Track
Lung cancer in women Abstract 1190P Specificities of lung cancer in never-smoking women J. Mazieres, Thoracic Oncology, CHU Toulouse - Hôpital Larrey, Toulouse/FRANCE
Poster presentation II
Sunday, September 30, 2012; 13:00 - 14:00
Abstract 1264P
Clinicopathologic features of never-smoking women lung cancer (WLC): a review from the Spanish World07 database
J. De Castro, Medical Oncology, Hospital Universitario La Paz, Madrid/SPAIN
Poster presentation I
Saturday, September 29, 2012; 13:00 - 14:00
"Although tobacco smoking accounts for the majority of lung cancers, lung cancer in never-smokers is a common disease. These two ESMO 2012 presentations deal with lung cancer in never-smoking women in Europe.
The findings of the French study underline the possibility that hormonal factors might be involved in lung cancer in never-smoking women. In samples of women diagnosed with lung cancer, the expression of estrogen receptor α and estrogen receptor β is higher in never-smoking when compared to smoking ones.
The 'WORLD07' is a database including prospectively clinical and pathological information of women diagnosed with lung cancer in 32 Spanish centers. Interestingly, never-smoking patients represent 39% of all women diagnosed with lung cancer. Forty percent of these never-smoking lung cancer patients have exposure to second-hand smoke.
Both independent studies show a high incidence of EGFR mutation in never-smoking women with lung cancer: 55% of the patients harbor EGFR mutation in the Spanish study and 51% in the French study."
Enriqueta Felip, Spain, Chair, ESMO 2012 Metastatic NSCLC Track
Cancer in adolescents
Abstract 1024PD
Surveillance of adolescents and young adult patients with Fanconi Anemia (FA): awareness of diagnosing solid tumors at a young age
J. Balmana, Medical Oncology, Hospital Vall d'Hebron, Barcelona, SPAIN
Head and neck cancer, Poster Discussion
Moderator: Temam, Prof. Dr.
Sunday, September 30, 2012; 13:00 - 14:00
Abstract 422P
Comparison of diagnostic and treatment delays of adolescent and young adult brain tumor patients with older adult brain tumor patients
Y. Xu, McGill Adolescent and Young Adult Oncology Program, Jewish General Hospital, McGill University, Montreal, QC, CANADA
Poster presentation II
Sunday, September 30, 2012; 13:00 - 14:00
"These are two very interesting studies concerning young patients. The first one reports an important experience from a specialized unit in Spain concerning young people affected with Fanconi anemia a recognized premalignant disease. The Spanish analysis highlights the benefits of a strict surveillance in this high-risk population.
In the second study, from Canada, an unacceptable delay in diagnosis and start of therapy was demonstrated in adolescents/young population affected with primary brain tumors in comparison with adults: according to the study results, the delay was mainly due to a lack of specific preparation and awareness of healthcare professionals.
As a whole, these observations emphasize the need for an active and high-quality approach to young people with suspected symptoms of cancer or at increased risk of developing some forms of cancer. To obtain it, well-trained teams are required, in all countries."
Roberto Labianca, Italy, ESMO Press & Media Affairs Committee
--> The studies listed below report important research in the area of biomarkers and developmental therapeutics, paving the way for future treatment and care of lung cancer patients, also highlighting possible treatment issues in clinical practice
Abstract 167O
Prevalence and clinical outcomes for patients with ALK gene rearrangement in Europe: preliminary results from the European Thoracic Oncology Platform Lungscape Project
F.H. Blackhall, Medical Oncology, The Christie NHS Foundation Trust, Manchester/UNITED KINGDOM
Biomarkers in lung cancer, Proffered Papers
Moderators: C. Caldas, Prof., J. Pierga, Prof
Saturday, September 29, 2012; 16:00 - 17:45
Abstract 438O
Phase II activity of the HSP90 inhibitor AUY922 in patients with ALK-rearranged (ALK+) or EGFR-mutated advanced non-small cell lung cancer (NSCLC)
E. Felip, Medical Oncology, Vall d´Hebron University Hospital, Barcelona/SPAIN
Abstract 439O
A first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies
S. Gettinger, Thoracic Oncology, Yale University School of Medicine, New Haven/UNITED STATES OF AMERICA
Abstract 440O
Results of a first-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors
A.T. Shaw, Hematology/oncology, Massachusetts General Hospital, Boston/UNITED STATES OF AMERICA
Abstract 441O
A phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLC; safety and efficacy interim results of the phase II portion
M. Nishio, Thoracic Oncology Center, Cancer Institute Hospital of JFCR, Tokyo/JAPAN
Developmental therapeutics, Proffered Papers
Moderators: T. Mitsudomi, Dr, C. Dittrich, Prof, E. Eisenhauer, Dr, S. Popat, Prof.
Saturday, September 29, 2012; 11:00 - 12:45
Abstract 1227O
Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors
NSCLC, metastatic I, Proffered Papers
Moderators: P. Baas, Prof, W. Eberhardt, Prof.
Sunday, September 30, 2012; 9:00 - 11:00
Abstract 1883P
Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): A European survey of Young Oncologists Committee - European Society for Medical Oncology (ESMO)
R. Califano, Young Oncologists Committee European Society For Medical Oncology, Medical Oncology, The Christie NHS Foundation Trust, Manchester/UNITED KINGDOM
Poster presentation II
Sunday, September 30, 2012; 1300 - 14:00
--> The following group of studies reveal significant data for breast cancer patients
Abstract 245O
A prospective randomized trial evaluating gene expression arrays to select neoadjuvant chemotherapy regimen for operable breast cancer: first report of the REMAGUS04 trial
J. Pierga, Medical Oncology, Institut Curie, Paris/FRANCE
Breast cancer, early stage, Proffered Papers
Moderators: P. Ellis, Dr, E. De Azambuja, Dr, I. Smith, Prof
Sunday, September 30, 2012; 14:00 - 15:45
Abstract 317O
First efficacy results from the TURANDOT phase III trial comparing two bevacizumab (bev)-containing regimens as first-line therapy for HER2-negative metastatic breast cancer (mbc)
C. Zielinski, Department Of Medicine I, Clinical Division Of Medical Oncology, Medical University of Vienna, Vienna/AUSTRIA
Breast cancer, metastatic, Proffered Papers
Moderators: L. Gianni, Dr, N. Turner, Dr
Monday, October 1, 2012; 13:55 - 15:55
Abstract 328PD
Progression-free survival as a surrogate for overall survival in metastatic breast cancer
C. Beauchemin, Faculty Of Pharmacy, University of Montreal, Montreal/CANADA
Breast cancer, locally advanced and metastatic, Poster Discussion
Moderators: T. Bachelot, Dr., G. Curigliano, Dr
Monday, October 1, 2012; 12:45 - 13:45
Abstract 288P
Prognostic Tools in Early Breast Cancer: Predicting benefit of adjuvant chemotherapy
E.E. Parkes, Medical Oncology, Northern Ireland Cancer Centre, Belfast/UNITED KINGDOM
Poster presentation III
Monday, October 1, 2012; 1300 - 14:00
Abstract 264P
Is there any difference in clinicopathological factors and prognosis of the young breast cancer?
Y. Kajiura, Breast Surgical Oncology, St Luke's International Hospital, Tokyo/JAPAN
Poster presentation III
Monday, October 1, 2012; 1300 - 14:00
--> The studies listed below describe new strategies for colorectal cancer
Abstract 518O
Maintenance treatment with immunomodulator MGN1703 following induction with standard 1st line therapy prolongs progression-free survival in patients with metastatic colorectal (MCRC): results of the phase II/III IMPACT trial
D. Arnold, University Cancer Centre Hamburg, Hubertus Wald Tumour CentreKMTZ, Hamburg/GERMANY
Gastrointestinal tumors, colorectal, Proffered Papers
Moderators: E. Diaz-Rubio, Dr., J. Douillard, Prof
Monday, October 1, 2012; 8:45 - 10:45
Abstract 522PD
Development and validation of a robust molecular diagnostic test (ColoPrint) for predicting outcome in stage II colon cancer patients
T. Bachleitner-Hofmann, Department Of Surgery, Medical University of Vienna, Vienna/AUSTRIA
Gastrointestinal tumors, colorectal, Poster Discussion
Moderators: J. Souglakos, Dr., M. Seymour, Prof, C.H. Köhne, Prof.
Saturday, September 29, 2012; 13:00 - 14:00
### Embargoes
These abstracts will be released on Monday, 17 September 2012 at 9:00 (CEST).
Late-breaking abstracts (LBA suffix) and studies included in the official ESMO Press Program (PR suffix) will remain under embargo until publicly released in connection with their presentation at the Congress or at one of the official daily ESMO Press Briefings.
Updated information on the ESMO 2012 Press Program is made available at http://www.esmo.org/events/vienna-2012-congress/press.html
Media Registration
ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration to the ESMO 2012 Congress is free to bona fide journalists on presentation of a letter of assignment and a valid press card.
To register for the event, please fill out the Complimentary Media Registration Form http://www.formstack.com/forms/esmo-media_registration_form
If you want to book one-on-one interviews with researchers and key opinion leaders, please email media@esmo.org.
About the European Society for Medical Oncology
The European Society for Medical Oncology (ESMO) is the leading European professional organization committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment and care.
ESMO's mission is to advance cancer care and cure through fostering and disseminating good science that leads to better medicine and determines best practice.
ESMO's scientific journal, Annals of Oncology, ranks among the top clinical oncology journals worldwide. ESMO events are the meeting place in Europe for medical oncologists to update their knowledge, to network and to exchange ideas.
To find out more about ESMO, please visit: www.esmo.org
